Immunicon Corporation to Introduce Repeat-Free(TM) Poseidon(TM) FISH Probes And Present Workshop and Posters at 2008 AACR Annual

  
    
  
  
    
      Immunicon Corporation (NASDAQ-GM:IMMC) will introduce its portfolio of 
      Repeat-Free™ Poseidon™ 
      FISH probes at the Annual Meeting of the American Association for Cancer 
      Research (AACR), the premier educational and scientific event in the 
      oncology research community, April 12-16 at the San Diego Convention 
      Center, San Diego California. In addition, Immunicon will participate in 
      a workshop on circulating tumor cells and present two posters on two new 
      rare cell detection kits based on CellTracks® 
      technology, circulating endothelial cell subsets and circulating 
      melanoma cells.
    
    
      Immunicon will exhibit the Repeat-Free™ 
      Poseidon™ FISH probes and the CellCapture™ 
      CTC Mouse/Rat Kit at booth number 2029. Immunicon believes that 
      Repeat-Free™ technology eliminates the need 
      to use blocking reagents and that RF Poseidon Probes reduces background 
      and provide brighter signals. Most importantly, RF Poseidon Probes need 
      only 4 hours of hybridization time to reach full signal strength, 
      compared to 16 hour hybridization time for traditional probes. Immunicon 
      believes that this workflow improvement combined with assay performance 
      represents clear competitive advantages in the field.
    
    
      The CellCapture™ CTC Mouse/Rat Kit enables 
      pre-clinical studies using circulating tumor cells (CTCs) in animal 
      models. The CellCapture™ Kit uses a manual 
      test procedure to capture CTCs in a few drops of mouse blood and the 
      cells are counted and characterized using the CellTracks® 
      Analyzer II. This kit will enable scientists to conduct efficacy studies 
      in very early drug studies and may streamline this important phase of 
      drug development. The CellCapture™ CTC Mouse 
      Kit and CellTracks® 
      Analyzer II are sold by the Immunicon sales team directly.
    
    
      
        
          
            Workshop: Circulating Tumor Cells
          
        
      
      
        
          
            Saturday, 1:00 PM-3:00 PM, Room 30A-C, San Diego Convention Center
          
        
      
      
        
          
            1:40 PM
          
        
        
           
        
        
          
            Monitoring and characterization of CTC in cancer patients
          
        
        
           
        
        
          
            Leon W.M.M. Terstappen, Immunicon Corporation, Huntingdon Valley, 
            PA
          
        
      
      
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          
            Poster Presentations
          
        
      
      
        
          
            Sunday, April 13
          
          
            1:00-5:00 PM
          
        
        
        
        
          
            Poster Section 12, Abstract #1083, Board 14
          
          
            Enumeration of VEGFR2 and Ki67 positive subsets of circulating 
            endothelial cells in blood
          
        
        
        
        
          Chandra Rao, Yao Yao, Mark Connelly, Mark Middleton, Gerald Doyle, 
          Leon Terstappen.
        
      
      
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Monday, April 14

          
            8:00 AM-12:00
          
        
        
        
        
          
            Poster Section 24, Abstract #2174, Board 19
          
          
            Cytogenetic analysis of Circulating Tumor Cells of metastatic 
            prostate cancer
          
        
        
        
        
          Arjan Gj Tibbe, Joost F. Swenenhuis, Rianne Levink, Ronald CJ 
          Sipkema, Leon WMM Terstappen.
        
      
      
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Tuesday, April 15

          
            8:00 AM-12:00
          
        
        
        
        
          
            Poster Section 12, Abstract #3695, Board 24
          
          
            Automated enumeration and characterization of circulating melanoma 
            cells in blood
          
        
        
        
        
          Chandra Rao, Thai Bui, Mark Connelly, Mark Middleton, Gerald Doyle, 
          Leon Terstappen.
        
      
      
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Tuesday, April 15

          
            8:00 AM-12:00
          
        
        
        
        
          
            Poster Section 12, Abstract #3693, Board 22
          
          
            Dynamics of circulating tumor cells in mice bearing human breast 
            cancer xenografts
          
        
        
        
        
          Jean-Pierre Eliane, Madeline Repollet, Kathryn E. Luker, Martha 
          Brown, James E. Rae, Gerald V. Doyle, Daniel F. Hayes, Gary D. Luker.
        
      
    
    
      Following the conference, the Immunicon presentations will be posted on 
      Immunicon’s Web site at http://www.immunicon.com. 
      For more about the 2008 AACR Annual Meeting, visit http://www.aacr.org/.
    
    
      About Immunicon Corporation
    
    
      Immunicon Corporation is developing and commercializing proprietary 
      cell- and molecular-based human diagnostic and life science research 
      products, and is providing certain analytical services to pharmaceutical 
      and biotechnology companies to assist them in developing new therapeutic 
      agents, with an initial focus on cancer disease management. Immunicon 
      has developed platform technologies to identify, count and characterize 
      a small number of rare cells in blood, such as circulating tumor cells 
      and circulating endothelial cells that are important in many diseases 
      and biological processes. Immunicon’s 
      products and underlying technology platforms also have application in 
      cancer research and may have applications in other fields of medicine, 
      such as cardiovascular and infectious diseases. For more information, 
      please visit www.immunicon.com.
    
    
      Forward-Looking Statements
    
    
      This press release may contain "forward-looking statements" within the 
      meaning of the Private Securities Litigation Reform Act of 1995. These 
      forward-looking statements are often preceded by words such as “hope,” 
      “may,” “believe,” 
      “anticipate,” “plan,” 
      “expect,” “intend,” 
      “assume,” “will” 
      and similar expressions. Forward-looking statements contained in this 
      press release include, among others, statements regarding the 
      anticipated clinical utility of Immunicon’s 
      products and other statements not of historical fact. Immunicon cautions 
      investors not to place undue reliance on these forward-looking 
      statements, which speak only as of the date of this press release, are 
      based on the current expectations and intent of the management of 
      Immunicon and involve certain factors, such as risks and uncertainties 
      that may cause actual results to be far different from those suggested 
      by these statements. These statements are not guarantees of future 
      performance and involve risks and uncertainties that are difficult to 
      predict, including, but not limited to, risks and uncertainties 
      associated with: Immunicon’s ability to 
      continue as a going concern; Immunicon’s 
      dependence on Veridex, LLC, a Johnson & Johnson company; the risks and 
      uncertainties with the arbitration proceeding with Veridex and the award 
      in favor of Veridex given Immunicon’s 
      dependencies on Veridex; the ability to earn license and milestone 
      payments under Immunicon’s agreement with 
      Veridex; Immunicon’s capital and financing 
      needs; research and development and clinical trial expenditures; 
      commercialization of product candidates; Immunicon’s 
      ability to obtain licenses from third parties to commercialize products; 
      Immunicon’s ability to manage its growth; 
      obtaining necessary regulatory approvals; reliance on third party 
      manufacturers and suppliers; reimbursement by third party payors to 
      Immunicon’s customers; compliance with 
      applicable manufacturing standards; retaining key personnel; delays in 
      the development of new products or planned improvements to products; 
      effectiveness of products compared to competitors’ 
      products; protection of Immunicon’s 
      intellectual property; conflicts with third party intellectual property; 
      product liability lawsuits that may be brought against Immunicon; labor, 
      contract or technical difficulties; and competitive pressures in 
      Immunicon’s industry. These factors are 
      discussed in more detail in Immunicon’s 
      filings with the Securities and Exchange Commission. Except as required 
      by law, Immunicon accepts no responsibility for updating the information 
      contained in this press release beyond the published date, whether as a 
      result of new information, future events or otherwise, or for 
      modifications made to this document by Internet or wire services.
    
    
      “Immunicon,” “CellTracks” 
      and the Immunicon Corporation logo are registered trademarks of 
      Immunivest Corporation, a subsidiary of Immunicon Corporation. 
      Repeat-Free is a trademark of Immunivest Corporation. Poseidon is a 
      trademark of Kreatech Diagnostics. ALL RIGHTS RESERVED.